🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

HBIO HBIO

Company Profile ↓
$6.37
+44.77% 1Y
P/E-4.98
52W High$7.90
52W Low$3.80
EPS (TTM)$-1.28

Company Overview

HBIO (HBIO) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $86.55M (-8.1% YoY); net profit $-56.70M.
  • Trailing 12 Months Year-on-year growth — revenue -8.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 0.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:0.06%
1 Year:-8.06%

Stock Price Performance

1 Year:+44.77%
6 Months:+27.40%
3 Months:-3.92%
1 Month:-3.92%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 63% of range
$3.80 $7.90
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.21 · Neutral
Price Performance
1M-3.92%
3M-3.92%
6M+27.40%
1Y+44.77%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.98
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
0.06%
Profit 5Y
-
Revenue (YoY)
-8.06%
Earnings (YoY)
-

Profitability & Returns

ROCE
-83.60%
ROE
-
ROA
-70.81%
Profit Margin
-65.51%
Op Margin
-56.13%
Gross Margin
57.67%
EPS (Latest Qtr)
$-0.77
EPS (TTM)
$-1.28

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$77.94M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
9.48%
Chg in Prom Hold
-
FII / Inst Holding
41.46%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$86.55M
EBITDA
-
Free Cash Flow
$5.47M
Operating Cash Flow
$6.73M
Shares Outstanding
-
Gross Margin
57.67%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue -------------26.76M31.52M28.64M33.86M28.20M29.58M27.42M30.97M23.77M23.31M24.04M26.99M29.20M29.66M28.78M29.21M26.92M29.98M28.76M25.36M24.51M23.10M21.97M21.77M20.45M20.59M20.75M
Gross Profit 13.86M11.48M12.60M11.73M12.92M12.95M11.68M11.69M12.11M9.58M9.07M9.50M11.02M13.27M15.36M15.82M18.74M16.15M15.96M14.98M17.23M12.98M13.86M13.49M15.43M16.35M16.31M16.18M16.64M12.17M18.35M16.67M14.73M14.77M13.22M12.77M12.18M11.53M12.02M12.24M
Operating Income 2.12M-1.15M99.00K-775.00K113.00K-221.00K-840.00K-813.00K-1.12M-350.00K-269.00K-390.00K374.00K-1.27M-382.00K890.00K1.74M-120.00K228.00K-1.36M1.63M-3.27M556.00K182.00K-239.00K58.00K548.00K-6.71M4.00M-3.76M1.75M796.00K-933.00K-2.28M-2.07M-1.87M-49.67M-819.00K197.00K-1.17M
Net Income -19.00K-1.40M349.00K-847.00K-17.14M-636.00K-713.00K-1.64M-1.32M-1.07M-381.00K-417.00K999.00K-4.06M-1.46M-256.00K2.86M-2.37M-247.00K-2.62M550.00K-4.52M-1.58M-1.10M-669.00K-410.00K-170.00K-6.88M2.44M-3.40M622.00K-980.00K-1.24M-4.69M-2.93M-4.80M-50.34M-2.28M-1.23M-3.42M
Diluted EPS 0.00-0.040.01-0.02-0.51-0.02-0.02-0.05-0.04-0.03-0.01-0.010.03-0.11-0.04-0.010.08-0.06-0.01-0.070.02-0.12-0.04---0.01--0.170.06-0.080.01-0.02-0.03-0.11-0.07-0.11-11.42-0.05-0.03-0.77
R&D Expense -1.75M1.71M1.43M-1.43M1.50M1.31M-1.28M1.30M1.54M-2.40M2.76M2.78M-2.73M2.77M2.56M-2.49M1.90M1.95M2.49M2.70M2.66M3.22M3.50M2.76M2.90M2.96M2.76M2.88M2.63M2.57M2.32M2.19M2.13M2.33M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 85.77M108.18M108.86M111.17M105.17M108.66M108.66M104.52M77.41M120.77M116.18M102.10M118.90M113.33M112.25M94.14M86.55M
Gross Profit 41.68M51.81M50.19M52.34M47.70M49.34M48.72M48.41M39.17M63.18M64.32M58.04M67.65M60.82M66.07M54.77M49.91M
Operating Income 8.05M10.22M8.40M7.83M1.54M6.62M-1.71M-3.00M-635.00K984.00K377.00K221.00K2.07M-6.93M1.89M-6.21M-48.58M
Net Income 7.23M19.02M3.81M2.37M-1.83M2.35M-19.04M-4.31M-865.00K-2.92M-4.69M-7.81M-288.00K-9.52M-3.42M-12.40M-56.70M
Diluted EPS 0.240.650.130.08-0.060.07-0.57-0.13-0.02-0.08-0.12---0.23-0.08-0.28-1.28
R&D Expense 4.40M4.67M3.87M4.34M4.15M4.88M6.42M5.39M5.64M10.99M10.71M8.69M10.80M12.33M11.76M10.41M8.82M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --124.80M126.63M133.48M135.46M135.92M120.05M107.77M109.35M-168.61M164.87M156.25M162.34M145.36M137.37M126.64M80.07M
Total Equity 66.72M75.26M90.25M95.50M104.21M94.48M95.47M77.60M72.20M80.90M-82.72M81.69M76.68M83.40M72.22M73.07M63.34M13.73M
Cash & Equivalents 13.70M16.59M19.70M17.92M20.68M25.77M14.13M6.74M5.60M5.19M-8.17M8.34M8.32M7.82M4.51M4.28M4.11M8.61M
Long Term Debt --18.01M16.30M12.95M19.75M16.45M16.37M11.37M8.98M11.90M54.81M46.92M46.29M45.09M43.01M30.70M035.87M
Total Liabilities --34.55M31.14M29.27M40.98M40.45M42.45M35.57M28.45M-85.89M83.18M79.57M78.94M73.14M64.29M63.30M66.34M
Current Liabilities --11.30M9.56M9.90M16.09M18.10M19.32M14.60M14.04M-25.49M25.31M21.05M25.32M23.25M26.54M54.96M21.96M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 16.51M12.29M6.65M8.06M4.06M4.35M705.00K5.38M1.06M2.88M8.04M9.33M1.26M1.15M14.03M1.44M6.73M
Investing Cash Flow -22.30M-8.35M-7.20M-4.68M171.00K-13.52M-7.52M-62.00K-917.00K-53.80M-229.00K-1.40M-1.34M-1.59M-1.80M-1.34M-1.86M
Financing Cash Flow 9.79M-31.00K-1.14M-1.06M68.00K-1.23M-540.00K-4.87M-1.79M53.05M-7.62M-7.97M-252.00K-2.84M-12.13M-131.00K-1.29M
Capital Expenditure ---------890.00K-986.00K-1.22M-1.15M-1.20M-1.59M-1.79M-2.64M-1.26M
Free Cash Flow --------167.00K1.90M6.83M8.18M67.00K-438.00K12.24M-1.20M5.47M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 48.6%47.9%46.1%47.1%45.4%45.4%44.8%46.3%50.6%52.3%55.4%56.8%56.9%53.7%58.9%58.2%57.7%
Operating Margin % 9.4%9.4%7.7%7.0%1.5%6.1%-1.6%-2.9%-0.8%0.8%0.3%0.2%1.7%-6.1%1.7%-6.6%-56.1%
Net Margin % 8.4%17.6%3.5%2.1%-1.7%2.2%-17.5%-4.1%-1.1%-2.4%-4.0%-7.6%-0.2%-8.4%-3.0%-13.2%-65.5%
ROE % 9.6%21.1%4.0%2.3%-1.9%2.5%-24.5%-6.0%-1.1%-3.5%-5.7%-10.2%-0.3%-13.2%-4.7%-19.6%-412.8%
ROCE % -9.0%7.2%6.3%1.3%5.6%-1.7%-3.2%-0.7%0.7%0.3%0.2%1.5%-5.7%1.7%-8.7%-83.6%

Shareholding Pattern

Insiders
9.48%
Institutions
41.46%
Public Float
45.80%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HBIO

Google News ue, 28 Jul 2026

Harvard Bioscience to release quarter results before market opens Aug. 11 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOQ3E5SHJZNkRFT3NqeW1RY2RDT3NDRUY1MDNFX2hrM09jVW1GM1I5NlR4RUlTb0RYZ3lTSHBjcHJzRzNGSGVKd2pYb054VUl2UllKU0pwSkJYMTM2a2U4ZHZ1Y1JkOEN0U0tJUUxPZ2cyV2ZzQ3BnaDhTU284aFQtYzNWQkxKUDItUHVobW…

Google News Fri, 31 Jul 2026

HBIO|Harvard Bioscience Inc|Price:6.330|Chg%:+0.230 - TradingKey

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE91N3ZxYmtVZ05hWm9JTEtFLVNUUmUzQ3d3Zmg4WDR0MGZtUHhFTGsyTHJGUXZnbWZCSkwtLUJ1cWZUNkFfQUlkQWhBWmdBVXUtajdDY3dKVnRGNUpCaHRtdE9UUnJFWktXcmd2Q3h3?oc=5" target="_blank">HBIO|Harvard Biosci…

Google News hu, 25 Jun 2026

HBIO Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1PdGhnV1BzLXBDNlNBOEdhSW5NQUZOV2tia0hrRy1KTThMTlVDdTNnc1pPZGpnVktBcmhLeHVHYlRCemJsRDZXeDNlZ3hyd0FIcDZtcHo1Qms4OFJJWlVSc2ZWYUo2Znl0OUFFaW9NeG4xYjhXYTFsWFdB?oc=5" target="_blank">HBI…

Google News hu, 07 May 2026

When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPMVhVdDVGVl9JeElKSk9zaF9DOXJvMkk2UWZCSjV5cTZXalNSdkd1aVE1ZzFWamhPQWxyOUJxeFJGenAyMk5IQ2VSdm5TRmxhN0ViV3hOQi1IOTU1MUFtMGY0amhiVTlYV2wtV1V4TUx1a2Y4cWlwa0dabEd5cVVkMFpiLU9hU2gtREpIYU…

Google News Wed, 01 Apr 2026

Harvard Bioscience CFO Frost buys $25,000 in HBIO stock - Investing.com

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPUDlBNk1aUm5DMno5dzM3SlRhY0VfY0VuUEY0MUt2N01ac2M1V0FucXJNLW1qZXNsdjYtWDlrRkRxRkhVaERfYzlsNmR6Skk3dWswQ2pzRmw1RVdqa3RvUjVRQWFaRmdfWlVJeGlQdGt1ZV9WaVRMWWdTRVhBWjItSzZyRXBwYzhFa081bE…

Google News Sun, 02 Aug 2026

HBIO Q1 2026 Earnings: Loss Narrower Than Expected, Stock Ticks Up 0.16 - Revenue Surprise History - dars.gov.et

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNSktzLU1lMFpfOFZmSUpWckM0TGYzS1BvQ0RnOE50Rk10eFNDeHU2ZnNTVGpZbzNFZVNvZkUtZ2wyX0ZqS0Nwemd6STZ6MGJvZlU3cWlIQnVhMjNubHVrTHRocDI1UDRza1hIZUxFR1pLWDVJUlI3bGpnQzBMRWU3U0UwcmRVY1dmckZBeU…

HBIO — Frequently Asked Questions

What is the current share price of HBIO?

As of 2026-08-05 17:25 PDT, HBIO trades at $6.37 on NASDAQ/NYSE. Its 52-week range is $3.80 to $7.90.

What is the P/E ratio of HBIO?

HBIO trades at a trailing price-to-earnings (P/E) ratio of -4.98.

Is HBIO a good stock to buy?

This page provides a data-driven analysis of HBIO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space